ClinicalTrials.gg
TerminatedNCT06833190NATRIX-SBPUpdated Oct 23, 2025

REGN5381 in Adult Participants With Uncontrolled Hypertension

A Phase 2 interventional study of REGN5381 and Placebo in Uncontrolled Hypertension, sponsored by Regeneron Pharmaceuticals. Terminated at 3 sites in United Kingdom. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-10-23.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 223 studies in Hypertension with a site in United Kingdom — 35 open to participants now, 43 under way, 7 of them phase 3. Hypertension · United Kingdom.

Enrollment
138th of 172
34 · median 125
Started
2025
with 12 others
Phase 2
26 of 223
none open now
Registered
208th of 223
by date

Among the 223 studies in Hypertension with a site in United Kingdom, this one is the 138th largest by enrollment of the 172 interventional ones that give a count, is one of 13 that started in 2025, is one of 26 in phase 2, and was the 208th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

35 of the 223 studies in Hypertension with a site in United Kingdom are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 223 studies in Hypertension with a site in United Kingdom, or all of them as a file.
02

Study summary

This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on uncontrolled hypertension (high blood pressure despite being on one or more antihypertensive drugs).

The aim of the study is to see how effective the study drug is in reducing blood pressure. The study is designed as a 2-part study with participants initially enrolling in Part A. Part B of the study will commence and enroll the remaining study participants.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Read the detailed description

As of October 15, 2025, this study has been terminated, and all future onsite visits have been canceled. However, participants have been asked to report safety information to the trial helpline until January 15, 2026.

03

Conditions studied

  • Uncontrolled Hypertension

Browse trials for

Keywords

  • High blood pressure
  • Systolic Blood Pressure (SBP)
04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Adults with SBP ≥130 mm Hg and SBP ≤180 mm Hg at both screening and randomization visit, as described in the protocol
  2. ≥ 40 and ≤85 years on a stable regimen of ≥1 anti-hypertensive therapy for at least 1 month at the time of screening or ≥30 and \<40 years on a stable regimen of ≥3 anti-hypertensive therapies for at least 1 month at the time of screening

Key Exclusion Criteria

  1. Heart rate >100 bpm as described in the protocol
  2. >45 kg/m2 as described in the protocol
  3. (GFR) \<30 mL/min/1.73m2 at screening as described in the protocol
  4. (AST) and Alanine aminotransferase (ALT) ≥3x (ULN) as described in the protocol

NOTE: Other protocol-defined Inclusion/Exclusion Criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    REGN5381 Low Dose

    Randomized as described in the protocol

    Drug: REGN5381

  • Experimental
    REGN5381 High Dose

    Randomized as described in the protocol

    Drug: REGN5381

  • Placebo comparator
    Placebo

    Randomized as described in the protocol

    Drug: Placebo

Interventions

  • Administered per the protocol

  • DrugPlacebo

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Unattended Automated Office-Based Blood Pressure (AOBP) Systolic Blood Pressure (SBP)

    Time frame: At week 12

Secondary outcomes

  1. Unattended AOBP SBP in stage 3 Chronic Kidney Disease (CKD) participants

    Time frame: At week 12

  2. Unattended AOBP SBP in participants on ≥3 anti-hypertensive therapies

    Time frame: At week 12

  3. Time-weighted average AOBP SBP

    Time frame: Through week 12

  4. Time-weighted average AOBP Diastolic Blood Pressure (DBP)

    Time frame: Through week 12

  5. AOBP SBP

    Time frame: From baseline to weeks 2, 4 and 8

  6. AOBP DBP

    Time frame: From baseline to weeks 2, 4, 8 and 12

  7. Mean SBP by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)

    Time frame: At week 12

  8. Concentrations of REGN5381 in serum

    Time frame: Through week 20

  9. Occurrence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to week 23

  10. Severity of TEAEs

    Time frame: Up to week 23

  11. Occurrence of TEAEs leading to discontinuation of study drug

    Time frame: Up to week 23

  12. Occurrence of Anti-Drug Antibodies (ADAs) to REGN5381

    Time frame: Through week 20

  13. Titer of ADAs to REGN5381

    Time frame: Through week 20

07

Study locations

3 sites
  • Protas, Car Park of Asda Huyton Supercentre
    Huyton, Liverpool L36 7TX, United Kingdom
  • Protas, Two New Bailey Square
    Salford, Manchester M3 5GS, United Kingdom
  • Protas, Car Park of Asda Pilsworth Road
    Bury, BL9 8RS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Oct 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2025
First posted
Feb 18, 2025
StartActual
Apr 16, 2025
Primary completionActual
Oct 15, 2025
CompletionActual
Oct 15, 2025
Last update
Oct 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06833190
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Apr 16, 2025
Primary completion
Oct 15, 2025
Completion
Oct 15, 2025
Last update
Oct 23, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vixticibart

Start the discussion